Recent Updates
Recently added Catalysts

Nizatidine

Phase 1

Healthy | Small molecule | Other |Dr. Reddy's Laboratories Ltd|Last Updated: Jul 14, 2010

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLEDDMC
Total Trials2
Total Enrollment52

FDA Designations

No designations recorded

Clinical trial landscape

Nizatidine · 2 trials · 1 indication

Phase 1 2
NCT01161927Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting ConditionsHealthy
COMPLETED26 Analytics
NCT01161940Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting ConditionsHealthy
COMPLETED26 Analytics
PHASE1COMPLETED
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Non- Fasting Conditions
HealthyUnlock trial analytics
PHASE1COMPLETED
Bioequivalence Study of Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Bioequivalence based on Cmax and AUC parameters
3 Months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
NizatidineEXPERIMENTALNizatidine Capsules 300 mg of Dr.Reddy'sLaboratories Limited
AxidACTIVE_COMPARATORAxid 300 mg Capsules of Reliant Pharmaceuticals, US

Interventions

NameTypeDescription
NizatidineDRUGNizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
AxidDRUGAxid 300 mg Capsules of Reliant Pharmaceuticals, US
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexMALE
Healthy VolunteersYes

Inclusion Criteria: * Healthy males between 18 and 55 years of age (inclusive) living in and around Ahmedabad city of western part of India. * Having a Body Mass Index (BMI) ≥ 18.0 kg/m2 (calculated as weight in kg/ height in m2). * Have no significant diseases or clinically significant abnormal fi...

Unlock Eligibility Criteria

Frequently asked questions about Nizatidine

What is Nizatidine used for?

Nizatidine is a small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development by Dr. Reddy's Laboratories Ltd. The ongoing research focuses on bioequivalence of the 300 mg capsule formulation under fasting and non-fasting conditions.

Who makes Nizatidine?

Nizatidine is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company is conducting Phase 1 clinical trials to evaluate the bioequivalence of its 300 mg nizatidine capsules.

What phase is Nizatidine in?

Nizatidine is in Phase 1 clinical development. Two Phase 1 bioequivalence studies have been completed, each enrolling 26 healthy male volunteers aged 18 years and older. The drug is investigational and has not been approved for marketing.

What clinical trials is Nizatidine in?

Nizatidine has two completed Phase 1 clinical trials. NCT01161927 is a bioequivalence study of nizatidine capsules 300 mg under non-fasting conditions, and NCT01161940 is the same study under fasting conditions. Both trials enrolled healthy male volunteers and were active-controlled.

Is Nizatidine the same as a generic drug?

Nizatidine is being studied as a generic version of the drug. The clinical trials conducted by Dr. Reddy's Laboratories Ltd are bioequivalence studies comparing their 300 mg nizatidine capsules to a reference product under fasting and non-fasting conditions in healthy volunteers.